Here are the 424B prospectus supplements from POLOMAR HEALTH SVCS INC (PMHS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PMHS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMHS filings page.
Polomar Health Services, Inc. has registered up to 7,710,219 shares of common stock for resale by existing stockholders. The company will not receive any proceeds from these sales; all proceeds go to the selling stockholders, who may sell at a fixed price of $0.20 per share until any national exchange or OTCQX/OTCQQB listing, and thereafter at market prices. As of December 11, 2025, 28,053,090 shares of common stock were outstanding, and the stock last closed at $0.08 on the OTCID Basic Market.
Polomar operates a Florida-licensed specialty compounding pharmacy, focusing on dermatology, GLP‑1 weight loss drugs and men’s health, and holds a license to patent‑pending inhalable formulations such as sildenafil. It is a development-stage business with a history of losses, significant related‑party debt and substantial doubt about its ability to continue as a going concern without new financing. A pending merger with Altanine Inc. is expected, if completed, to leave Altanine holders owning about 80% of the combined company, subject to numerous conditions including a Nasdaq listing and a reverse stock split.